Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Switzerland’s drug authority has granted approval for the first malaria medication specifically designed for infants and ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

A new malaria treatment has been approved for newborns and infants under 11lbs, filling a major gap in care for some of the most vulnerable children.

Novartis has received approval for Coartem Baby, the world's first malaria treatment specifically for newborns and young ...

Kenya is among eight African countries that participated in clinical trials for a newly approved malaria treatment, ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and in-depth features. Reclaim your full access. Click below to renew.

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made ...

The first malaria treatment specifically developed for newborn babies and young infants has been approved for use.   The approval, by Switzerland’s medical agency Swissmedic, of Coartem Baby ...

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis AG, with a price target of CHF89.00. The company’s shares opened today at CHF97.91. According to ...